Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced?

Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced?

ABSTRACTObjectives: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the most important curative modality for several hematologic malignancies, but an HLA-matched sibling or unrelated donor is not always available, particularly for ethnic minorities and multiethnic families. We have...

Full description

Bibliographic Details
Main Authors: Juan Carlos Olivares-Gazca, María de Lourdes Pastelín-Martínez, Merittzel Abigail Montes-Robles, Moisés Manuel Gallardo-Pérez, Edgar J. Hernández-Flores, Max Robles-Nasta, Daniela Sánchez-Bonilla, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Hematology
Subjects:
Allogeneic hematopoietic stem cell transplantation
Post-transplantation Cyclophosphamide
Graft-versus-host disease; Outpatient; Cytokine release syndrome; Allograft; Haploidentical hematopoietic stem cell transplantation; Acute leukemia
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2023.2242176

Similar Items

Similar Items